Sevibe Cells


SEVIBE CELLS S.L. specializes in the storage and preservation of cord blood and stem cells, providing advanced cellular therapies and biobanking services across Europe, Asia, Africa, and America. They emphasize the importance of conserving cord blood stem cells for future medical use and are part of the FamiCord group, the largest cord blood bank group in Europe. The company is committed to innovation, research, and offering comprehensive services related to cellular therapies, including the collection, storage, and application of stem cells for various medical conditions.

Industries

biotechnology
health-care
health-diagnostics
wellness

Nr. of Employees

small (1-50)

Sevibe Cells

Barcelona, Catalonia, Spain, Europe


Products

Private cord-blood biobanking service

Service package covering collection, in-house processing, quality-controlled preparation and long-term cryogenic storage of an umbilical cord-blood unit for private clients.


Services

End-to-end service covering coordination of cord-blood collection at birth, in-house laboratory processing, quality-controlled preparation and long-term cryogenic storage of the processed unit.

Telephone and online consultations, informational guides and week-by-week pregnancy content to support decision-making on cord-blood services; optional virtual or in-person laboratory viewing.

Preparation-for-birth streaming course and webinar series covering labour, analgesia, breastfeeding, newborn care and postnatal recovery delivered via gated video content.

Publication of curated news articles and summaries discussing clinical advances, research findings and events related to stem-cell science and cellular therapies.

Online pricing information plus personalized quotation and contract handling for private cord-blood storage services.

Expertise Areas

  • Cord-blood biobanking and cryopreservation
  • In-house laboratory processing and sample handling
  • Laboratory accreditation, quality systems and validation
  • Sample logistics and chain-of-custody management
  • Show More (6)

Key Technologies

  • Cryogenic biobanking and inventory management
  • Umbilical cord blood processing workflows
  • Cold-chain and sample transport logistics
  • Laboratory quality-control and validated workflows
  • Show More (4)

News & Updates

A patient survives over 18 years after receiving CAR-T therapy for neuroblastoma, demonstrating the long-term potential of cellular immunotherapy.

Researchers from VHIO and HMRI have developed a new CAR-T therapy targeting p95HER2, showing promising preclinical results and moving towards clinical trials.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.